Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Nov 4, 2026.

Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer

Paloma Cejas, Yingtian Xie, Alba Font-Tello and 35 more (opens in a new tab)

Nature Communications · 2021 · CC BY

doi:10.1038/s41467-021-26042-z (opens in a new tab)

Abstract

Neuroendocrine carcinomas (NEC) are tumors expressing markers of neuronal differentiation that can arise at different anatomic sites but have strong histological and clinical similarities. Here we report the chromatin landscapes of a range of human NECs and show convergence to the activation of a common epigenetic program. With a particular focus on treatment emergent neuroendocrine prostate cancer (NEPC), we analyze cell lines, patient-derived xenograft (PDX) models and human clinical samples to show the existence of two distinct NEPC subtypes based on the expression of the neuronal transcription factors ASCL1 and NEUROD1. While in cell lines and PDX models these subtypes are mutually exclusive, single-cell analysis of human clinical samples exhibits a more complex tumor structure with subtypes coexisting as separate sub-populations within the same tumor. These tumor sub-populations differ genetically and epigenetically contributing to intra- and inter-tumoral heterogeneity in human metastases. Overall, our results provide a deeper understanding of the shared clinicopathological characteristics shown by NECs. Furthermore, the intratumoral heterogeneity of human NEPCs suggests the requirement of simultaneous targeting of coexisting tumor populations as a therapeutic strategy.

References 67

  1. 1.
    Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas · 2017
    Not checked
  2. 2.

    Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010;39:707-712.

    Not in our library10.1097/mpa.0b013e3181ec124e (opens in a new tab)

  3. 3.

    Rickman DS, Beltran H, Demichelis F, Rubin MA. Biology and evolution of poorly differentiated neuroendocrine tumors. Nat. Med. 2017;23:1-10.

    Not in our library10.1038/nm.4341 (opens in a new tab)

  4. 4.

    Cheng J, et al. Merkel cell polyomavirus recruits MYCL to the EP400 complex to promote oncogenesis. PLoS Pathog. 2017;13:e1006668.

    Not in our library10.1371/journal.ppat.1006668 (opens in a new tab)

  5. 5.

    Aggarwal R, et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. J. Clin. Oncol. 2018;36:2492-2503.

    Not in our library10.1200/jco.2017.77.6880 (opens in a new tab)

  6. 6.

    Oser MG, Niederst MJ, Sequist LV, Engelman JA. Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. Lancet Oncol. 2015;16:e165-e172.

    Not in our library10.1016/s1470-2045(14)71180-5 (opens in a new tab)

  7. 7.

    Rudin CM, et al. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nat. Rev. Cancer. 2019;19:289-297.

    Not in our library10.1038/s41568-019-0133-9 (opens in a new tab)

  8. 8.

    Neptune ER, et al. Targeted disruption of NeuroD, a proneural basic helix-loop-helix factor, impairs distal lung formation and neuroendocrine morphology in the neonatal lung. J. Biol. Chem. 2008;283:21160-21169.

    Not in our library10.1074/jbc.m708692200 (opens in a new tab)

  9. 9.

    Ito T, et al. Basic helix-loop-helix transcription factors regulate the neuroendocrine differentiation of fetal mouse pulmonary epithelium. Development. 2000;127:3913-3921.

    Not in our library10.1242/dev.127.18.3913 (opens in a new tab)

  10. 10.
    ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs · 2016
    Not checked
  11. 11.

    Balanis NG, et al. Pan-cancer convergence to a small-cell neuroendocrine phenotype that shares susceptibilities with hematological malignancies. Cancer Cell. 2019;36:17-34.e7.

    Not in our library10.1016/j.ccell.2019.06.005 (opens in a new tab)

  12. 12.

    Nguyen HM, et al. LuCaP prostate cancer patient-derived xenografts reflect the molecular heterogeneity of advanced disease and serve as models for evaluating cancer therapeutics. Prostate. 2017;77:654-671.

    Not in our library10.1002/pros.23313 (opens in a new tab)

  13. 13.

    Drapkin BJ, et al. Genomic and functional fidelity of small cell lung cancer patient-derived xenografts. Cancer Disco. 2018;8:600-615.

    Not in our library10.1158/2159-8290.cd-17-0935 (opens in a new tab)

  14. 14.

    Corces, M. R. et al. The chromatin accessibility landscape of primary human cancers. Science362, eaav1898 (2018).

    Not in our library10.1126/science.aav1898 (opens in a new tab)

  15. 15.

    Park JW, et al. Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage. Science. 2018;362:91-95.

    Not in our library10.1126/science.aat5749 (opens in a new tab)

  16. 16.

    Labrecque MP, et al. Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. J. Clin. Invest. 2019;129:4492-4505.

    Not in our library10.1172/jci128212 (opens in a new tab)

  17. 17.

    McLean CY, et al. GREAT improves functional interpretation of cis-regulatory regions. Nat. Biotechnol. 2010;28:495-501.

    Not in our library10.1038/nbt.1630 (opens in a new tab)

  18. 18.

    Heinz S, et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol. Cell. 2010;38:576-589.

    Not in our library10.1016/j.molcel.2010.05.004 (opens in a new tab)

  19. 19.

    Fan K, et al. MCPyV large T antigen-induced atonal homolog 1 is a lineage-dependency oncogene in Merkel cell carcinoma. J. Invest. Dermatol. 2020;140:56-65.e3.

    Not in our library10.1016/j.jid.2019.06.135 (opens in a new tab)

  20. 20.

    Park DE, et al. Author correction: Merkel cell polyomavirus activates LSD1-mediated blockade of non-canonical BAF to regulate transformation and tumorigenesis. Nat. Cell Biol. 2020;22:752.

    Not in our library10.1038/s41556-020-0533-9 (opens in a new tab)

  21. 21.

    Augustyn A, et al. ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers. Proc. Natl. Acad. Sci. USA. 2014;111:14788-14793.

    Not in our library10.1073/pnas.1410419111 (opens in a new tab)

  22. 22.

    Denny SK, et al. Nfib promotes metastasis through a widespread increase in chromatin accessibility. Cell. 2016;166:328-342.

    Not in our library10.1016/j.cell.2016.05.052 (opens in a new tab)

  23. 23.

    Rudin CM, et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat. Genet. 2012;44:1111-1116.

    Not in our library10.1038/ng.2405 (opens in a new tab)

  24. 24.

    Horie M, et al. An integrative transcriptome analysis reveals a functional role for thyroid transcription factor-1 in small cell lung cancer. J. Pathol. 2018;246:154-165.

    Not in our library10.1002/path.5109 (opens in a new tab)

  25. 25.

    Zheng R, et al. Cistrome data browser: expanded datasets and new tools for gene regulatory analysis. Nucleic Acids Res. 2019;47:D729-D735.

    Not in our library10.1093/nar/gky1094 (opens in a new tab)

  26. 26.

    Layer RM, et al. GIGGLE: a search engine for large-scale integrated genome analysis. Nat. Methods. 2018;15:123-126.

    Not in our library10.1038/nmeth.4556 (opens in a new tab)

  27. 27.

    Borges M, et al. An achaete-scute homologue essential for neuroendocrine differentiation in the lung. Nature. 1997;386:852-855.

    Not in our library10.1038/386852a0 (opens in a new tab)

  28. 28.

    Ashburner M, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat. Genet. 2000;25:25-29.

    Not in our library10.1038/75556 (opens in a new tab)

  29. 29.

    DeLucia DC, et al. Regulation of CEACAM5 and therapeutic efficacy of an anti-CEACAM5-SN38 antibody-drug conjugate in neuroendocrine prostate cancer. Clin. Cancer Res. 2021;27:759-774.

    Not in our library10.1158/1078-0432.ccr-20-3396 (opens in a new tab)

  30. 30.

    Saint-André V, et al. Models of human core transcriptional regulatory circuitries. Genome Res. 2016;26:385-396.

    Not in our library10.1101/gr.197590.115 (opens in a new tab)

  31. 31.

    Wapinski OL, et al. Rapid chromatin switch in the direct reprogramming of fibroblasts to neurons. Cell Rep. 2017;20:3236-3247.

    Not in our library10.1016/j.celrep.2017.09.011 (opens in a new tab)

  32. 32.

    Matsushita M, et al. Neural differentiation of human embryonic stem cells induced by the transgene-mediated overexpression of single transcription factors. Biochem. Biophys. Res. Commun. 2017;490:296-301.

    Not in our library10.1016/j.bbrc.2017.06.039 (opens in a new tab)

  33. 33.

    Beltran H, et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat. Med. 2016;22:298-305.

    Not in our library10.1038/nm.4045 (opens in a new tab)

  34. 34.

    Butler A, Hoffman P, Smibert P, Papalexi E, Satija R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 2018;36:411-420.

    Not in our library10.1038/nbt.4096 (opens in a new tab)

  35. 35.
    CopywriteR: DNA copy number detection from off-target sequence data · 2015
    No notice
  36. 36.

    Satpathy AT, et al. Massively parallel single-cell chromatin landscapes of human immune cell development and intratumoral T cell exhaustion. Nat. Biotechnol. 2019;37:925-936.

    Not in our library10.1038/s41587-019-0206-z (opens in a new tab)

  37. 37.

    Ireland AS, et al. MYC drives temporal evolution of small cell lung cancer subtypes by reprogramming neuroendocrine fate. Cancer Cell. 2020;38:60-78.e12.

    Not in our library10.1016/j.ccell.2020.05.001 (opens in a new tab)

  38. 38.

    Culine S, et al. Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers. J. Urol. 2007;178:844-848.

    Not in our library10.1016/j.juro.2007.05.044 (opens in a new tab)

  39. 39.

    Aparicio AM, et al. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin. Cancer Res. 2013;19:3621-3630.

    Not in our library10.1158/1078-0432.ccr-12-3791 (opens in a new tab)

  40. 40.

    Taplin, M. E. et al. A phase 1b/2 study of CPI-1205, a small molecule inhibitor of EZH2, combined with enzalutamide (E) or abiraterone/prednisone (A/P) in patients with metastatic castration resistant prostate cancer (mCRPC). J. Clin. Oncol. 37, TPS398-TPS398 (2018).

    Not in our library

  41. 41.

    Clermont P-L, et al. Polycomb-mediated silencing in neuroendocrine prostate cancer. Clin. Epigenetics. 2015;7:40.

    Not in our library10.1186/s13148-015-0074-4 (opens in a new tab)

  42. 42.

    Ku SY, et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science. 2017;355:78-83.

    Not in our library10.1126/science.aah4199 (opens in a new tab)

  43. 43.

    Kareta MS, et al. Inhibition of pluripotency networks by the Rb tumor suppressor restricts reprogramming and tumorigenesis. Cell Stem Cell. 2015;16:39-50.

    Not in our library10.1016/j.stem.2014.10.019 (opens in a new tab)

  44. 44.

    Asangani IA, et al. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature. 2014;510:278-282.

    Not in our library10.1038/nature13229 (opens in a new tab)

  45. 45.

    Asangani IA, et al. BET bromodomain inhibitors enhance efficacy and disrupt resistance to AR antagonists in the treatment of prostate cancer. Mol. Cancer Res. 2016;14:324-331.

    Not in our library10.1158/1541-7786.mcr-15-0472 (opens in a new tab)

  46. 46.

    Welti J, et al. Targeting bromodomain and extra-terminal (BET) family proteins in castration-resistant prostate cancer (CRPC). Clin. Cancer Res. 2018;24:3149-3162.

    Not in our library10.1158/1078-0432.ccr-17-3571 (opens in a new tab)

  47. 47.

    Saunders LR, et al. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci. Transl. Med. 2015;7:302ra136.

    Not in our library10.1126/scitranslmed.aac9459 (opens in a new tab)

  48. 48.

    Dylla SJ. Toppling high-grade pulmonary neuroendocrine tumors with a DLL3-targeted trojan horse. Mol. Cell. Oncol. 2016;3:e1101515.

    Not in our library10.1080/23723556.2015.1101515 (opens in a new tab)

  49. 49.

    Mollaoglu G, et al. MYC drives progression of small cell lung cancer to a variant neuroendocrine subtype with vulnerability to aurora kinase inhibition. Cancer Cell. 2017;31:270-285.

    Not in our library10.1016/j.ccell.2016.12.005 (opens in a new tab)

  50. 50.

    Corces, M. R. et al. Omni-ATAC-seq: improved ATAC-seq protocol. Protocol exchange. 10.1038/protex.2017.096 (2017).

    Not in our library

  51. 51.

    Buenrostro JD, et al. Single-cell chromatin accessibility reveals principles of regulatory variation. Nature. 2015;523:486-490.

    Not in our library10.1038/nature14590 (opens in a new tab)

  52. 52.

    Whyte WA, et al. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell. 2013;153:307-319.

    Not in our library10.1016/j.cell.2013.03.035 (opens in a new tab)

  53. 53.

    Qin, Q. et al. ChiLin: a comprehensive ChIP-seq and DNase-seq quality control and analysis pipeline. BMC Bioinformatics17, 404 (2016).

    Not in our library10.1186/s12859-016-1274-4 (opens in a new tab)

  54. 54.

    Qiu, X. et al. CoBRA: containerized bioinformatics workflow for reproducible ChIP/ATAC-seq analysis. Genomics Proteomics Bioinformatics10.1016/j.gpb.2020.11.007 (2021).

    Not in our library10.1016/j.gpb.2020.11.007 (opens in a new tab)

  55. 55.

    Thorvaldsdóttir H, Robinson JT, Mesirov JP. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief. Bioinformatics. 2013;14:178-192.

    Not in our library10.1093/bib/bbs017 (opens in a new tab)

  56. 56.

    Ji X, Li W, Song J, Wei L, Liu XS. CEAS: cis-regulatory element annotation system. Nucleic Acids Res. 2006;34:W551-W554.

    Not in our library10.1093/nar/gkl322 (opens in a new tab)

  57. 57.
    VIPER: Visualization Pipeline for RNA-seq, a Snakemake workflow for efficient and complete RNA-seq analysis · 2018
    No notice
  58. 58.

    Dobin A, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15-21.

    Not in our library10.1093/bioinformatics/bts635 (opens in a new tab)

  59. 59.
    GSVA: gene set variation analysis for microarray and RNA-Seq data · 2013
    No notice
  60. 60.
    Pooling across cells to normalize single-cell RNA sequencing data with many zero counts · 2016
    No notice
  61. 61.

    Cibulskis K, et al. ContEst: estimating cross-contamination of human samples in next-generation sequencing data. Bioinformatics. 2011;27:2601-2602.

    Not in our library10.1093/bioinformatics/btr446 (opens in a new tab)

  62. 62.

    Cibulskis K, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 2013;31:213-219.

    Not in our library10.1038/nbt.2514 (opens in a new tab)

  63. 63.

    Saunders CT, et al. Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs. Bioinformatics. 2012;28:1811-1817.

    Not in our library10.1093/bioinformatics/bts271 (opens in a new tab)

  64. 64.

    Benjamin, D. et al. Calling Somatic SNVs and Indels with Mutect2. Preprint at bioRxiv10.1101/861054 (2019).

    Not in our library

  65. 65.

    Taylor-Weiner A, et al. DeTiN: overcoming tumor-in-normal contamination. Nat. Methods. 2018;15:531-534.

    Not in our library10.1038/s41592-018-0036-9 (opens in a new tab)

  66. 66.

    Carter SL, et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 2012;30:413-421.

    Not in our library10.1038/nbt.2203 (opens in a new tab)

  67. 67.

    Jo S-Y, Kim E, Kim S. Impact of mouse contamination in genomic profiling of patient-derived models and best practice for robust analysis. Genome Biol. 2019;20:231.

    Not in our library10.1186/s13059-019-1849-2 (opens in a new tab)

Cited by papers we hold 4

Questions about this paper

We email you if it is retracted, withdrawn, corrected or flagged.

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.